Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).

Eleni Efstathiou,Myrto Boukovala,Nicholas Spetsieris,Sijin Wen,Anh Hoang,Justin Alexander Weldon,Rebecca Slack-Tidwell,John W. Davis,Brian F. Chapin,Paul G. Corn,Sumit K. Subudhi,Ana Aparicio,Curtis A. Pettaway,Louis L. Pisters,John N. Papadopoulos,Mehrad Adibi,Jennifer Wang,Amado J. Zurita,Christopher J. Logothetis,Patricia Troncoso

Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).

2020

5504Background: Novel androgen signaling inhibitors (ASI) with medical castration may improve outcomes in LHRPC. We previously reported relapse free survival association with pathologic measures of...

Keywords:

Abiraterone
Apalutamide
Oncology
Internal medicine
Prostate cancer
Pathology
Medicine

Correction
Source
Cite
Save

References

Citations